FIELD: biotechnology.
SUBSTANCE: group of inventions is described, including a pharmaceutical composition for inhibition, delay, or reduction in growth of malignant cells in subject suffering from cancer (options), and a method for inhibition, delay, or reduction in growth of malignant cells in a subject suffering from cancer, including administration to the subject of the above-mentioned pharmaceutical composition. In one of implementations, the pharmaceutical composition contains effective amount of an antibody or its antigen-binding fragment, specifically binding to semaphorin 4D (SEMA4D), and epigenetic modulating agent selected from entinostat and azacytidine.
EFFECT: invention expands the arsenal of means for inhibition, delay, or reduction in growth of malignant cells in a subject suffering from cancer.
26 cl, 12 dwg, 4 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| EARLY DETECTION OF ACTIVATION OF GLIAL CELLS IN NEURODEGENERATIVE OR NEUROINFLAMMATORY DISEASES | 2018 |
|
RU2766341C2 |
| HUMAN ANTIBODIES AGAINST SEMAPHORIN 4D | 2018 |
|
RU2776443C2 |
| COMBINATION THERAPY WITH SEMAFORIN 4D (SEMA4D) BLOCKING AND DC1 THERAPY | 2020 |
|
RU2801828C2 |
| ANTI-PD-1 ANTIBODIES | 2017 |
|
RU2752832C2 |
| ANTIBODIES AGAINST CD40 AND THEIR USE | 2018 |
|
RU2796413C2 |
| MONOCLONAL ANTIBODIES AGAINST HUMAN TIM-3 | 2019 |
|
RU2777336C1 |
| ANTI-GARP-TGF-β-ANTIBODIES | 2018 |
|
RU2767784C2 |
| BINDING MOLECULES, NAMELY ANTIBODIES CAPABLE OF BINDING TO L1CAM (CD171) | 2015 |
|
RU2754684C2 |
| HUMANIZED ANTIBODIES SPECIFIC TO ALPHA-ENOLASE AND METHODS FOR USE IN ANTITUMOR THERAPY | 2014 |
|
RU2761662C2 |
| ANTIBODIES OF DOGS WITH MODIFIED CH2-CH3 SEQUENCES | 2014 |
|
RU2687209C1 |
